Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and Year Ended March 31, 2026
Nature of Filing / Announcement: Outcome of Board Meeting and Audited Financial Results
Audit Opinion:
Unmodified opinion from statutory auditors Walker Chandiok & Co LLP on both standalone and consolidated financial results.
Key Financial Highlights [All figures in ₹ Lakhs]:
Consolidated Results:
For Year Ended March 31, 2026:
- Revenue from Operations: ₹4,388.07 Cr
- Total Income: ₹4,428.60 Cr
- Net Profit: ₹277.91 Cr
- EPS: ₹17.59 (Basic), ₹17.51 (Diluted)
- Other Equity: ₹31,104.50 Cr
- Cash and Cash Equivalents: ₹1,884.70 Cr
- Total Debt: ₹78,107 Cr (Non-current borrowings ₹32,211 Cr + Current borrowings ₹45,888 Cr)
For Quarter Ended March 31, 2026:
- Revenue from Operations: ₹1,178.65 Cr
- Total Income: ₹1,187.96 Cr
- Net Profit: ₹86.44 Cr
- EPS: ₹5.47 (Basic), ₹5.39 (Diluted)
YoY Comparison (Consolidated FY26 vs FY25):
- Revenue from Operations: Increased from ₹4,177.61 Cr to ₹4,388.07 Cr
- Net Profit: Increased from ₹263.42 Cr to ₹277.91 Cr
Standalone Results:
For Year Ended March 31, 2026:
- Revenue from Operations: ₹4,138.49 Cr
- Total Income: ₹4,238.18 Cr
- Net Profit: ₹267.97 Cr
- EPS: ₹16.82 (Basic and Diluted)
- Other Equity: ₹26,241.30 Cr
- Cash and Cash Equivalents: ₹1,646.70 Cr
- Total Debt: ₹70,470 Cr (Non-current borrowings ₹22,536 Cr + Current borrowings ₹47,934 Cr)
For Quarter Ended March 31, 2026:
- Revenue from Operations: ₹1,093.47 Cr
- Total Income: ₹1,139.50 Cr
- Net Profit: ₹105.22 Cr
- EPS: ₹6.60 (Basic and Diluted)
Segment-wise Performance [₹ in Lakhs]:
Consolidated Segment Revenue (FY26):
- Speciality Chemicals: ₹19,365.0 Cr
- Nutrition & Health Solutions: ₹7,897.0 Cr
- Chemical Intermediates: ₹16,618.7 Cr
Consolidated Segment Profit before tax (FY26):
- Speciality Chemicals: ₹4,103.8 Cr
- Nutrition & Health Solutions: ₹79.4 Cr
- Chemical Intermediates: ₹(-21.7) Cr
Standalone Segment Revenue (FY26):
- Speciality Chemicals: ₹21,399.2 Cr
- Nutrition & Health Solutions: ₹7,226.1 Cr
- Chemical Intermediates: ₹15,605.3 Cr
Standalone Segment Profit before tax (FY26):
- Speciality Chemicals: ₹4,778.9 Cr
- Nutrition & Health Solutions: ₹303.7 Cr
- Chemical Intermediates: ₹(-217.3) Cr
Corporate Actions:
- Board recommended a final dividend of ₹2.5 per equity share (face value ₹1 each) amounting to ₹3,982 lakhs for FY26, subject to shareholder approval
- Total dividend for FY26 amounts to ₹7,964 lakhs (₹5 per share), including interim dividend of ₹2.5 per share declared in Q3 FY26
- 9,469 equity shares allotted during the quarter upon exercise of vested stock options
Other Significant Information:
Exceptional Items:
- One-time charge of ₹13.04 Cr (consolidated) and ₹12.22 Cr (standalone) due to implementation of New Labour Codes effective November 21, 2025
- Impact relates to changes in employee benefit computations due to revised definition of 'wages'
Acquisition:
- Acquired 100% stake in Remidex Pharma Private Limited on March 30, 2026 for ₹16.28 Cr
- Strategic move to expand into premixes for human nutrition and pharmaceutical manufacturing
Entities in Consolidation:
Includes 8 subsidiaries and 3 associates, with Remidex Pharma becoming subsidiary from March 30, 2026
Key Ratios (Consolidated FY26):
- Debt Service Coverage Ratio: 4.39 times
- Interest Service Coverage Ratio: 12.36 times
- Operating Margin: 8.92%
- Net Profit Margin: 6.28%
- Debt Equity Ratio: 0.19 times
- Current Ratio: 1.29 times